Home › Novartis' Zykadia Approved for Frontline Treatment of Metastatic, ALK-Positive NSCLC

Novartis' Zykadia Approved for Frontline Treatment of Metastatic, ALK-Positive NSCLC

May 30, 2017

This article has been updated with additional information about the availability of an FDA-approved companion diagnostic for Zykadia. Roche announced FDA approved its Ventana ALK (D5F3) test on June 1.

NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved an expanded indication for Novartis' Zykadia (ceritinib), making it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  2. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

  3. Precipio Reports 140 Percent Jump in Preliminary Q3 Revenues

  4. Digital Pathology Startup Deep Lens Emerges From Stealth Mode

  5. DiaCarta Lands $2M SBIR Grant to Develop Radiation Toxicity Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.